MetaVia Inc.
MTVA
Clasificación en acciones
#32902
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Precio por acción
$1.28
Última sincronización: 2026-10-20
Capitalización bursátil
$8.43M
Cambio (1 día)
4.07%
Cambio (1 año)
-21.47%
País
US
Comercio MetaVia Inc. (MTVA)
Categoría
Healthcare
Historial de desdoblamientos de acciones de MetaVia Inc. (MTVA)
La acción MetaVia Inc. (símbolo: MTVA) tuvo un total de 3 desdoblamientos.
El desdoblamiento más reciente ocurrió el Dec 21, 2023.
Una acción MTVA comprada antes de Dec 31, 2019 equivaldría hoy a 0.00016666666666667 acciones MTVA.
El desdoblamiento más reciente ocurrió el Dec 21, 2023.
Una acción MTVA comprada antes de Dec 31, 2019 equivaldría hoy a 0.00016666666666667 acciones MTVA.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| 2023-12-21 | 1:8 | x0.125 | x0.00016666666666667 |
| 2022-09-13 | 1:30 | x0.033333333333333 | x0.0013333333333333 |
| 2019-12-31 | 1:25 | x0.04 | x0.04 |
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
